Lipocine Inc. (LPCN) stock
LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3043% below fair value
$1.50−0.02 (-1.32%)
Close on Nov 19, 2026Market cap $12.37MP/E –Yield –
Lipocine free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Lipocine's free cash flow for the twelve months ending Dec 31, 2024 was -$1.31M. For fiscal 2024 it was -$1.31M. The highest annual figure on record is -$1.31M in fiscal 2024.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$1.31M | – |
| FY2023 | Dec 31, 2023 | -$11.88M | – |
| FY2022 | Dec 31, 2022 | -$12.10M | – |
| FY2021 | Dec 31, 2021 | -$4.42M | – |
| FY2018 | Dec 31, 2018 | -$12.08M | – |
| FY2017 | Dec 31, 2017 | -$16.70M | – |
| FY2016 | Dec 31, 2016 | -$18.34M | – |
| FY2015 | Dec 31, 2015 | -$15.38M | – |
| FY2014 | Dec 31, 2014 | -$17.36M | – |
| FY2013 | Dec 31, 2013 | -$8.59M | – |
| FY2012 | Dec 31, 2012 | -$3.19M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | $1.69M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.03M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.61M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.31M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.93M | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.94M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.20M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.06M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.91M | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.30M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.57M | – |
| Q2 FY2017 | Jun 30, 2017 | -$4.70M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.14M | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.55M | – |
| Q3 FY2016 | Sep 30, 2016 | -$4.05M | – |
See a number that looks wrong?